Physician profile
Joseph M Lavi
NPI 1912082017
$10,325.08
in general payments reported to CMS, 2019-2025
45 companies · $1,273 in 2025
The $1,273 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,804 · 2020: $665 · 2021: $1,518 · 2022: $1,695 · 2023: $1,791 · 2024: $1,579 · 2025: $1,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,643.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,519.15 | 2019-2025 | |
| Novo Nordisk INC | $1,359.63 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $951.02 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $871.39 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $735.25 | 2019-2025 | Jardiance, Tradjenta, Stiolto Respimat |
| Pfizer INC. | $494.84 | 2019-2024 | |
| Lilly USA, LLC | $443.06 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $420.56 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $398.16 | 2019-2024 | Pifeltro, Delstrigo, Verquvo |
| Amgen INC. | $353.37 | 2019-2025 | Evenity, Prolia, Repatha |
| E.R. Squibb & Sons, L.L.C. | $328.74 | 2019-2024 | Eliquis |
| Optinose US, INC. | $251.40 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $174.14 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $171.02 | 2019-2022 | |
| Angiodynamics, INC. | $145.56 | 2024 | Auryon Laser System 100-120 Vac |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Lavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.